Efficacy of the VIALE ‐A Regimen for AML With Monocytic Differentiation as Determined by French‐American‐British Subtyping and Gene Expression Profiling

Documenti analoghi

• Analysis of Patients With Monocytic and Monocytic‐Like Acute Myeloid Leukemia, Including AML ‐ M4 and AML ‐ M5 , Treated With Venetoclax Plus Azacitidine
  di: Marina Konopleva, et al.
  Pubblicazione: (2026)
• Venetoclax in the treatment of acute myeloid leukemia: Beyond VIALE‐A
  di: Naseema Gangat, et al.
  Pubblicazione: (2024)
• Long‐term follow‐up of VIALE‐A: Venetoclax and azacitidine in chemotherapy‐ineligible untreated acute myeloid leukemia
  di: Keith W. Pratz, et al.
  Pubblicazione: (2024)
• Real‐World Outcomes of FLAG ‐Ida Regimen in 1079 Adult Patients With First Relapsed/Refractory AML : A PETHEMA Study
  di: Gaspar Aspas Requena, et al.
  Pubblicazione: (2026)
• Ontogeny and Natural History of Therapy‐Related Clonal Hematopoiesis From a Multidisciplinary CHIP Clinic
  di: Shyam A. Patel, et al.
  Pubblicazione: (2026)